GSK says it aims to bring FDA-approved antibody therapy to India for Covid

Treatment with Sotrovimab resulted in an 85 per cent reduction in the risk of hospitalization, says company.

Britain’s GlaxoSmithKline (GSK) and Nasdaq-listed Vir Biotechnology have won the US drug regulator’s approval for a drug to treat mild and moderate Covid-19 patients older than 12.

A spokesperson for GSK India said that the company was exploring options to make Sotrovimab, an "important medicine", available for Indian patients quickly. The spokesperson did not comment on possible pricing of the product that will be available in the US in weeks. “Discussions with global regulators regarding authorisations in additional countries continue to advance,” GSK said.

Cipla recently launched its Roche antibody cocktail (casrivimab and imdevimab) for Rs 60,000 per patient for